Cosmos Health Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. The unaudited filing was signed November 20, 2023. Cosmos Health operates pharmaceutical wholesale and distribution, pharmaceutical manufacturing, and proprietary nutraceutical businesses, principally in Greece and other international markets.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $12.82 million | $12.02 million | $37.54 million | $38.30 million |
| Gross profit | $1.21 million | $1.78 million | $3.12 million | $5.52 million |
| Gross margin | 9.5% | 14.8% | 8.3% | 14.4% |
| Operating loss | $3.02 million | $0.34 million | $8.24 million | $0.18 million |
| Net loss | $3.35 million | $1.97 million | $4.79 million | $3.01 million |
- Q3 revenue increased 6.7% year over year; nine-month revenue declined 2.0%. Q3 revenue was predominantly from Greece ($12.54 million).
- Gross profit and margins contracted as lower-margin wholesale activity made up more of sales and the company discounted nutraceutical sales while seeking to reduce overdue Medihelm receivables.
- Nine-month operating cash outflow was $16.59 million, versus $4.55 million a year earlier. Investing cash outflow was $10.40 million; financing provided $8.40 million. Cash fell to $2.36 million from $20.75 million at year-end 2022.
- At September 30, working capital was $23.90 million, down from $34.62 million at year-end. Total assets were $71.53 million and total liabilities $26.96 million. Current liabilities included $5.35 million of lines of credit; notes payable totaled $4.22 million, of which $1.06 million was current. No convertible notes remained outstanding.
- Accounts receivable, net, was $25.59 million, with a $7.74 million doubtful-account allowance. Inventory was $5.96 million. The company reported $44.20 million in stockholders’ equity and a $71.04 million accumulated deficit.
Material changes and unusual items
- Operating expenses rose materially: nine-month general and administrative costs were $6.66 million versus $3.19 million, and salaries and wages were $3.28 million versus $1.68 million. Management cited higher compensation, bonuses, stock-based compensation, and marketing costs.
- The June 30 acquisition of Cana added manufacturing operations and assets. The company recognized a $1.63 million bargain-purchase gain; Cana contributed $91,056 of Q3 revenue and a $604,790 Q3 loss.
- Nine-month other income included $1.91 million of debt-extinguishment gains and the Cana bargain-purchase gain. These items helped limit the reported nine-month net loss despite the $8.24 million operating loss.
- Q3 included a $579,387 provision for extraordinary tax charges and $836,300 of bad-debt expense for the nine-month period. The filing also reports a $317,129 revenue reduction for the nine months under variable-consideration accounting for overdue Medihelm receivables.
- The July 2023 registered direct offering and concurrent warrant issuance generated approximately $5.25 million in gross proceeds; the cash-flow statement reports $9.95 million of common-stock proceeds for the nine months, including other proceeds. Common shares outstanding were 12,982,196 at September 30 and 13,404,204 as of November 20. The filing reports approximately 6.12 million warrants outstanding at September 30.
Outlook, risks, and controls
- Going concern: Management states that substantial doubt exists about the company’s ability to continue as a going concern for twelve months from the filing date. It says revenue is insufficient to sustain operations and that the company may need additional financing. Planned equity financing and warrant exercises, cost reductions, product expansion, acquisitions, and vertical integration are not assured.
- Business plans: Management described plans to expand distribution and proprietary brands, pursue acquisitions and R&D, and grow the nutraceutical portfolio to 150 SKUs by the end of 2023. These are plans, not assured forecasts; the filing provides no quantified financial guidance.
- Risks: The filing cites financing needs, competition, dependence on key products and individuals, supply-chain and regulatory pressures, economic conditions, foreign-exchange exposure, and potential changes in government reimbursement and pharmaceutical pricing. A Montreal property purchase agreement totals $3.95 million; $2.00 million had been advanced by quarter-end, with closing scheduled for December 31, 2023.
- Related parties: The company reports significant Doc Pharma balances, including $5.49 million in prepayments and $1.98 million in receivables at September 30. Doc Pharma is associated with the CEO’s family, manufactures the company’s nutraceutical products, and is a key supplier.
- Legal and regulatory matters: The filing describes a Greek medicines-agency fine of €15,000 related to a wholesale-license matter and a pending appeal seeking recovery of previously paid tax and fines of €91,652. Management says the listed litigation matters are not expected to have a material financial or operational impact.
- Internal controls: Management concluded disclosure controls were ineffective because of a material weakness: the company lacked a formal transaction-approval authority chart. The filing notes the $3.95 million Montreal property agreement had not been formally approved by the board and was to be submitted for ratification.
- Subsequent event: On October 9, 2023, the company agreed to acquire an AI drug-repositioning platform for €300,000 payable in installments plus 280,000 restricted shares valued at $700,000.
Important facts for investors to verify
- Whether operating cash use, receivable collections, supplier prepayments, and near-term liquidity improve after quarter-end—and how the company expects to fund operations.
- Whether the going-concern financing plans were completed, and the resulting dilution from share issuance and warrant exercise.
- Collection status and credit quality of Medihelm and other receivables, including the related-party balances and the adequacy of the bad-debt allowance.
- Whether gross margins recover as sales mix changes, and whether Cana and acquired distribution assets contribute as management expects.
- Final board approval and funding/closing status of the Montreal property purchase, and progress addressing the disclosed control weakness.
- Actual performance and consideration issued for the AI platform acquisition, and any material developments in the disclosed tax or licensing matters.